Latent tuberculosis infection in myasthenia gravis patients on immunosuppressive therapy: high incidence yet moderate reactivation rate
Authors:
Open Access
- 14 November 2023
- journal article
- research article
- Published by Taylor & Francis in Annals of Medicine
- Vol. 55 (2)
Abstract
Immunosuppressive therapies (ISTs) are mainstays for management of myasthenia gravis (MG). Meanwhile, latent tuberculosis infection (LTBI) is common in the setting of high-burden countries. However, the prevalence of LTBI among MG patients and whether receiving ISTs for MG would aggravate LTBI reactivation remain unknown. We retrospectively analyzed the frequency of LTBI via interferon-gamma release assay (IGRA) positivity among hospitalized MG patients from both rural and urban areas in a tertiary hospital, and those receiving ISTs were followed up to investigate the reactivation risk of LTBI. A total of 300 MG patients with determinate IGRA results were enrolled, where the frequency of LTBI was 35.0%. Male (OR = 1.910, 95% CI: 1.181–3.089, p = .008) and elderly (OR = 1.044, 95% CI: 1.027–1.061, p < .001) patients were prone to LTBI. Of those with LTBI, 78 individuals on ISTs were successfully followed up for a median duration of 18.3 (8.5–24.0) months, of which 25 (32.1%) received anti-tuberculosis (TB) treatments. The rate of various degrees of adverse events was 82.1% over the course of the follow-up, but was not different between individuals with and without therapies against TB (χ2 < 0.001, p > .999). Only 1 patient eventually reported lymph node and intestinal TB, with the incidence rate of LTBI reactivation preliminarily estimated to be 0.81 per 100 person years. The frequency of LTBI is high in our MG cohort, especially among those with advanced age and males. However, receiving immunosuppressives seems not to increase the risk of LTBI reactivation. LTBI screening is strongly recommended for all MG patients ready to receive ISTs, while preventive anti-TB chemotherapy should be prescribed after weighing potential benefits against the risk of side effects in those with LTBI. In-depth investigation is still entailed to further verify these findings due to the limitation of the retrospective single-center design of our study.Keywords
Funding Information
- National Natural Science Foundation of China (82171399)
This publication has 27 references indexed in Scilit:
- Preventive therapy for latent tuberculosis infection—the promise and the challengesInternational Journal of Infectious Diseases, 2017
- Biologic Agents and TuberculosisMicrobiology Spectrum, 2016
- Effect of immunosuppressive therapy on interferon γ release assay for latent tuberculosis screening in patients with autoimmune diseases: a systematic review and meta-analysisThorax, 2015
- Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practiceAutoimmunity Reviews, 2015
- Latent tuberculosis infection in rural China: baseline results of a population-based, multicentre, prospective cohort studyThe Lancet Infectious Diseases, 2015
- Higher risk of tuberculosis reactivation when anti-TNF is combined with immunosuppressive agents: a systematic review of randomized controlled trialsAnnals of Medicine, 2014
- Associations between selected immune-mediated diseases and tuberculosis: record-linkage studiesBMC Medicine, 2013
- Tuberculosis in myasthenia gravisThe International Journal of Tuberculosis and Lung Disease, 2013
- Utility of Interferon-γ Release Assay Results to Monitor Anti-Tubercular Treatment in Adults and ChildrenClinical Therapeutics, 2012
- Mechanisms of Clinically Relevant Drug Interactions Associated with TacrolimusClinical Pharmacokinetics, 2002